Table 1.
Comparison of clinical characteristics between COPD patients with eosinophilic and neutrophilic exacerbations
| Eosinophilic | Neutrophilic | P-value | |
|---|---|---|---|
| Subjects, n | 177 | 380 | |
| Male, n (%) | 151 (85.3) | 262 (68.9) | <0.001 |
| Age (years), mean ± SD | 69.89±11.25 | 73.06±9.34 | <0.001 |
| BMI, mean ± SD | 22.61±3.49 | 21.76±3.86 | 0.019 |
| Comorbidities, n (%) | |||
| Hypertension | 61 (34.5) | 145 (38.2) | 0.400 |
| DM | 35 (19.8) | 75 (19.7) | 0.992 |
| MI history | 8 (4.5) | 16 (4.2) | 0.867 |
| CHF | 10 (5.6) | 21 (5.5) | 0.953 |
| CVA history | 8 (4.5) | 21 (5.5) | 0.619 |
| Allergy history, n (%) | 9 (5.1) | 11 (2.9) | 0.270 |
| Asthma history, n (%) | 30 (16.9) | 73 (19.2) | 0.522 |
| Smoking history, n (%) | |||
| Never | 25 (14.1) | 98 (25.8) | 0.002 |
| Ex-smoker | 92 (52.0) | 168 (44.2) | 0.087 |
| Current smoker | 53 (29.9) | 100 (26.3) | 0.372 |
| Smoking (PY), mean ± SD | 41.39±26.59 | 36.25±28.76 | 0.069 |
| ≥1 hospital or ER admission in the previous year, n (%) | 46 (26.0) | 111 (29.2) | 0.431 |
| COPD medication, n (%) | |||
| ICS | 1 (0.6) | 8 (2.1) | 0.179 |
| LAMA | 77 (43.55) | 170 (44.7) | 0.785 |
| LABA | 11 (6.2) | 18 (4.7) | 0.465 |
| ICS + LABA | 71 (40.1) | 181 (47.6) | 0.097 |
| PDE4 inhibitor | 2 (1.1) | 19 (5.0) | 0.026 |
Abbreviations: SD, standard deviation; BMI, body mass index; DM, diabetes mellitus; MI, myocardial infarction; CHF, congestive heart failure; CVA, cerebrovascular accident; PY, pack-year; ER, emergency room; ICS, inhaled corticosteroids; LAMA, long-acting muscarinic antagonist; LABA, long-acting beta agonist; PDE4, phosphodiesterase 4.